Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

57.18 -3.82 (-6.26%)
Streaming Delayed Price Updated: 11:38 AM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 173,249
Open 60.29
Bid (Size) 56.92 (200)
Ask (Size) 57.29 (100)
Prev. Close 61.00
Today's Range 56.75 - 60.29
52wk Range 19.45 - 63.96
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Analysts Have This To Say About Kymera Therapeutics
 
Via Benzinga
Kymera Therapeutics Inc (NASDAQ:KYMR) Q3 2025 Earnings: Clinical Progress Overshadows Financial Miss
Kymera Therapeutics stock rises on positive clinical updates for its atopic dermatitis drug, KT-621, despite missing Q3 2025 revenue and EPS estimates. 
Via Chartmill

Performance

YTD
+39.8%
+39.8%
1 Month
+0.5%
+0.5%
3 Month
+40.0%
+40.0%
6 Month
+85.8%
+85.8%
1 Year
+15.6%
+15.6%

More News

Read More
Earnings Scheduled For November 4, 2025
Via Benzinga
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts
Via Benzinga
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
Via Benzinga
This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
What to Expect from Kymera Therapeutics's Earnings
Via Benzinga
What 6 Analyst Ratings Have To Say About Kymera Therapeutics
Via Benzinga
Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market
Via Chartmill
Topics Earnings
Kymera Revenue Drops 55 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock
Via Benzinga
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Earnings Scheduled For August 11, 2025
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
Via Stocktwits
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Via Benzinga
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
From Gilead Sciences, Inc.
Via Business Wire
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Via MarketBeat
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
Via Benzinga
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish
Via Stocktwits
Here are the top movers in Monday's session.
Via Chartmill
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga

Frequently Asked Questions

Is Kymera Therapeutics, Inc. - Common Stock publicly traded?
Yes, Kymera Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Kymera Therapeutics, Inc. - Common Stock trade on?
Kymera Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kymera Therapeutics, Inc. - Common Stock?
The ticker symbol for Kymera Therapeutics, Inc. - Common Stock is KYMR on the Nasdaq Stock Market
What is the current price of Kymera Therapeutics, Inc. - Common Stock?
The current price of Kymera Therapeutics, Inc. - Common Stock is 57.18
When was Kymera Therapeutics, Inc. - Common Stock last traded?
The last trade of Kymera Therapeutics, Inc. - Common Stock was at 11/07/25 11:38 AM ET
What is the market capitalization of Kymera Therapeutics, Inc. - Common Stock?
The market capitalization of Kymera Therapeutics, Inc. - Common Stock is 3.16B
How many shares of Kymera Therapeutics, Inc. - Common Stock are outstanding?
Kymera Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.